Non-specific interstitial pneumonia (NSIP) secondary to treatment with imatinib. A case report and review of the literature
DOI:
https://doi.org/10.32818/reccmi.a2n3a9Keywords:
imatinib, pulmonary fibrosis, chronic myeloid leukemiaAbstract
Imatinib is a powerful and selective inhibitor of the protein tirosine kinase BCR-ABL with clinical significant efficacy for the treatment of chronic myeloid leukemia (CML). Pulmonary toxicity induced by Imatinib has got a wide range of presentations and symptoms, being the interstitial neumonitis an exceptional example regarding literature. In this case, patients normally show a non specific interstitial neumonitis and evolution is generally good after treatment withdrawal and therapy with esteroids. We present the case of a 74-years-old male with interstitial neumonitis caused by Imatinib prescribed for CML in chronic phase.
Downloads
Metrics
References
O’Brien SG, Guilhot F, Larson RA, Gathmann I, Baccarani M, Cervantes F, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2003 Mar 13; 348(11): 994-1004. doi: https://doi.org/10.1056/NEJMoa022457.
Kantarjian H, Sawyers C, Hochhaus A, Guilhot F, Schiffer C, Gambacorti-Passerini C, et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med. 2002 Feb 28; 346(9): 645-652. Erratum in: N Engl J Med. 2002 Jun 13; 346(24): 1923. doi: https://doi.org/10.1056/NEJMoa011573.
Go SW, Kim BK, Lee SH, Kim TJ, Huh JY, Lee JM, et al. Successful Rechallenge with Imatinib in a Patient with Chronic Myeloid Leukemia Who Previously Experienced Imatinib Mesylate Induced Pneumonitis. Tuberc Respir Dis. 2013 Dec; 75(6): 256-259. doi: https://doi.org/10.4046/trd.2013.75.6.256.
Ohnishi K, Sakai F, Kudoh S, Ohno R. Twenty-seven cases of drug-induced interstitial lung disease associated with imatinib mesylate. Leukemia. 2006 Jun; 20(6): 1162-1164. doi: https://doi.org/10.1038/sj.leu.2404207.
Eşkazan AE, Salihoğlu A, Erturan S, Soysal T. Interstitial pneumonitis in a patient with chronic myeloid leukemia. Turk J Haematol. 2013 Dec; 30(4): 435-436. doi: https://doi.org/10.4274/Tjh.2012.0115. Epub 2013 Dec 5.
Lee NR, Jang JW, Kim HS, Yhim HY. Imatinib mesylate-induced interstitial lung disease in a patient with prior history of Mycobacterium tuberculosis infection. Korean J Intern Med. 2015 Jul; 30(4): 550-553. doi: https://doi.org/10.3904/kjim.2015.30.4.550.
Sugaya A, Ishiguro S, Mitsuhashi S, Abe M, Hashimoto I, Kaburagi T, et al. Interstitial lung disease associated with trastuzumab monotherapy: A report of 3 cases. Mol Clin Oncol. 2017 Feb; 6(2): 229-232. doi: https://doi.org/10.3892/mco.2016.1113.
Dimopoulou I, Bamias A, Lyberopoulos P, Dimopoulos MA. Pulmonary toxicity from novel antineoplastic agents. Ann Oncol. 2006 Mar; 17(3): 372-379. Epub 2005 Nov 16. Review. doi: https://doi.org/10.1093/annonc/mdj057.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2017 Carlos Azofra-Macarrón, Dimas Manuel Robaina-Cabrera, Manuela Anta-Fernández, Andrea González-Pascual, Carlos de Miguel-Sánchez
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Permite compartir, copiar y redistribuir el material en cualquier medio o formato, bajo los siguientes términos:
Reconocimiento: debe otorgar el crédito correspondiente, proporcionar un enlace a la licencia e indicar si se realizaron cambios. Puede hacerlo de cualquier manera razonable, pero no de ninguna manera que sugiera que el licenciante lo respalda a usted o su uso.
No comercial: no puede utilizar el material con fines comerciales.
No Derivados: si remezcla, transforma o construye sobre el material, no puede distribuir el material modificado.
Sin restricciones adicionales: no puede aplicar términos legales o medidas tecnológicas que restrinjan legalmente a otros de hacer cualquier cosa que permita la licencia.
